| Literature DB >> 33603072 |
Bo Ryoung Park1, Ki-Hye Kim1, Tatiana Kotomina2, Min-Chul Kim1,3, Young-Man Kwon1, Subbiah Jeeva1, Yu-Jin Jung1, Noopur Bhatnagar1, Irina Isakova-Sivak2, Daria Mezhenskaya2, Larisa Rudenko2, Bao-Zhong Wang1, Sang-Moo Kang4.
Abstract
Hemagglutinin (HA)-based current vaccines provide suboptimum cross protection. Influenza A virus contains an ion channel protein M2 conserved extracellular domain (M2e), a target for developing universal vaccines. Here we generated reassortant influenza virus rgH3N2 4xM2e virus (HA and NA from A/Switzerland/9715293/2013/(H3N2)) expressing chimeric 4xM2e-HA fusion proteins with 4xM2e epitopes inserted into the H3 HA N-terminus. Recombinant rgH3N2 4xM2e virus was found to retain equivalent growth kinetics as rgH3N2 in egg substrates. Intranasal single inoculation of mice with live rgH3N2 4xM2e virus was effective in priming the induction of M2e specific IgG antibody responses in mucosal and systemic sites as well as T cell responses. The rgH3N2 4xM2e primed mice were protected against a broad range of different influenza A virus subtypes including H1N1, H3N2, H5N1, H7N9, and H9N2. The findings support a new approach to improve the efficacy of current vaccine platforms by recombinant influenza virus inducing immunity to HA and cross protective M2e antigens.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33603072 PMCID: PMC7893060 DOI: 10.1038/s41598-021-83704-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379